Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

May 7, 2021

Study Completion Date

May 7, 2022

Conditions
Huntington's Disease
Interventions
OTHER

No Study Drug was Administered in this Study

No study drug was administered in this study

Trial Locations (15)

10117

Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi, Berlin

20007

Georgetown University; Research Division, Psychiatry, Washington D.C.

21287

John Hopkins University School of Medicine, Baltimore

44791

St. Josef and St. Elisabeth gGmbH ; St. Josef Hospital Bochum; Neurologisches Forschungszentrum, Bochum

67226

Hereditary Neurological Disease Centre (HNDC), Wichita

77030

The University of Texas Health Science Center at Houston; McGovern Medical School, Houston

80113

CenExel Rocky Mountain Clinical Research, LLC, Englewood

89081

Universitätsklinikum Ulm; Klinik für Neurologie, Ulm

10032-3725

Columbia University, New York

V6T 2B5

The University of British Columbia; The Centre for Huntington Disease, Vancouver

L6B 1C9

Centre for Movement Disorders (Neuropharm Consulting Inc.), Markham

B15 2FG

NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry, Birmingham

CF24 4HQ

Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences, Cardiff

WC1N 3BG

National Hospital For Neurology and Neurosurgery, London

M13 9WL

Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03664804 - Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease | Biotech Hunter | Biotech Hunter